Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-2671-2025

BioMerieux, Inc. recalls VITEK¿ 2 Gram-negative AST Test Kits (Cards) containing Colistin formulation cs02n.…

bioMerieux, Inc.Durham, NC, United StatesReported Oct 8, 2025 · 9 months ago
Legal News Analyst ·

Reason for recall

Potential for false resistant results for Colistin (cs02n) with multi-drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii complex used in specific cards

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

Affected products & lots

  • VITEK¿ 2 Gram-negative AST Test Kits (Cards) containing Colistin formulation cs02n. VITEK¿ 2 is an automated system consisting of instruments, software and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. Export only
    116 affected lots
    424840AST-N463424842AST-N465424891AST-N4751703184204424891
    +108 moreAST-N4751703225504424934AST-N4761713192504425019AST-N4771733184104425019AST-N4771733205204425019AST-N4771733205214424197AST-XN210493174204424197AST-XN210493310504424199AST-XN220552981204424199AST-XN220553156204424351AST-XN240653042204424351AST-XN240653217504424394AST-XN250662155104424394AST-XN250662553204424586AST-XN280793210504424586AST-XN280793265504424586AST-XN280793295504424586AST-XN280793210504424604AST-XN290822932204424604AST-XN290823262504424810AST-XN351323087204424888AST-XN371693079204AST-XN25424394AST-N412423936AST-XN21424197AST-XN22424199AST-N427424196AST-XN24424351AST-N439424501AST-N440424502AST-XN28424586AST-N443424541AST-N444424587AST-N447424620AST-N448424633AST-XN35424810AST-N462424839AST-N463424840AST-N465424842AST-XN37424888AST-N475424891AST-N476424934AST-N477425019AST-N438424499AST-XN29424604

What the firm is doing

On 06/27/2025, the firm sent an "URGENT FIELD SAFETY NOTICE" letter to customer informing them that VITEK 2 users, who are using VITEK 2 GN-AST cards with Colistin formulation, cs02n, have reported obtaining false resistant Colistin results with Acinetobacter baumannii complex and Pseudomonas aeruginosa isolates. Customers are required to: bioMrieux recommends you confirm any resistant colistin (cs02n) results for multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii complex isolates via an alternate method for all existing and future AST cards with cs02n. If appropriate for your laboratory, create a custom bioART rule to show when resistant colistin (cs02n) results are obtained for Pseudomonas aeruginosa and Acinetobacter baumannii complex isolates (refer to the VITEK 2 Software User Manual for instructions). Based on individual facility policy, you may wish to perform retrospective review of resistant results. Distribute this information to all appropriate personnel in your laboratory, retain a copy in your files, and forward this information to all parties that may use this product, including others to whom you may have transferred the product. Complete the Acknowledgement Form in Attachment A and return it to your local bioMrieux representative to confirm receipt of this notice. It is important that you return the acknowledgement form to bioMrieux even if you determine that this product correction notice does not impact your facility. For questions or further assistance, contact the local bioMerieux Customer Service Representative.

DistributionShow details

International distribution in the countries of Albania, Armenia, Australia, Austria, Belgium, Bosnia, Bulgaria, China, Croatia, Cyprus, Czech Republic/Slovakia, France, Germany, Greece, Iberia, India, Israel, Italy, Japan, Lithuania, Macedonia, Malaysia/Brunei, Moldova, Netherlands, Pakistan, Poland, Portugal, Romania, Russia, Serbia, South Korea, Spain, Switzerland, Taiwan, Thailand, and Turkey.

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls